Newswise News from Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Latest news from Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) on Newswise en-us Copyright 2024 Newswise Newswise News from Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 115 31 / /images/newswise-logo-rss.gif Making Connections will be the focus at the ACTRIMS Forum 2025 /articles/making-connections-will-be-the-focus-at-the-actrims-forum-2025/?sc=rsin /articles/making-connections-will-be-the-focus-at-the-actrims-forum-2025/?sc=rsin Thu, 01 Aug 2024 12:05:59 EST The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is excited to announce its tenth annual Forum, taking place from February 27 to March 1, 2025, at the Palm Beach County Convention Center and the Hilton West Palm Beach in Florida. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research /articles/national-ms-society-awards-dr-sergio-baranzini-the-barancik-prize-for-innovation-in-ms-research/?sc=rsin /articles/national-ms-society-awards-dr-sergio-baranzini-the-barancik-prize-for-innovation-in-ms-research/?sc=rsin Tue, 30 Jan 2024 11:05:48 EST Sergio E. Baranzini, PhD, a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco, is the winner of this year's Barancik Prize for Innovation in MS Research. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) The ninth annual ACTRIMS Forum will be held Feb. 29 - March 2 in West Palm Beach, Florida. /articles/the-ninth-annual-actrims-forum-will-be-held-feb-29-march-2-in-west-palm-beach-florida/?sc=rsin /articles/the-ninth-annual-actrims-forum-will-be-held-feb-29-march-2-in-west-palm-beach-florida/?sc=rsin Thu, 03 Aug 2023 11:30:05 EST Breaking Barriers in MS will be the focus at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Is it MS or Something Else? Updated Guide is Published to Expedite and Uncover the Answer /articles/is-it-ms-or-something-else-updated-guide-is-published-to-expedite-and-uncover-the-answer/?sc=rsin /articles/is-it-ms-or-something-else-updated-guide-is-published-to-expedite-and-uncover-the-answer/?sc=rsin Wed, 19 Jul 2023 18:30:00 EST An international consortium led by ACTRIMS has published detailed updated recommendations for how to distinguish suspected multiple sclerosis from other look-alike disorders. This critical guidance aims to reduce the time spent to confirm an accurate diagnosis of MS. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) ACTRIMS Forum 2023 themed MS: Going Viral /articles/actrims-forum-2023-themed-ms-going-viral/?sc=rsin /articles/actrims-forum-2023-themed-ms-going-viral/?sc=rsin Thu, 08 Sep 2022 13:05:32 EST The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual Forum will be held Feb. 23-25, 2023, in San Diego, California at the Marriott Marquis San Diego Marina. Themed "MS: Going Viral," the Forum 2023, will address the role of different viruses that have been implicated in the ongoing disease process in MS, in particular the Epstein-Barr virus, which has been associated with the onset of MS. The Forum also features the Kenneth P. Johnson Memorial Lecture, which will be delivered by Dr. Lawrence Steinman. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) ACTRIMS Board Member Dr. Amit Bar-Or Wins Barancik Prize for Innovation in MS Research /articles/actrims-board-member-dr-amit-bar-or-wins-barancik-prize-for-innovation-in-ms-research/?sc=rsin /articles/actrims-board-member-dr-amit-bar-or-wins-barancik-prize-for-innovation-in-ms-research/?sc=rsin Thu, 17 Feb 2022 16:05:59 EST The National MS Society announced that Amit Bar-Or, MD, the Melissa and Paul Anderson President's Distinguished Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania is this year's recipient of the Barancik Prize for Innovation in MS Research. He is being honored for work uncovering how the immune system drives MS and for cutting-edge research focusing on precision medicine to achieve long-term remission and ultimately preventing progression of the disease. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Evolution of the Neuroinflammatory Response Over the Clinical Course of MS /articles/evolution-of-the-neuroinflammatory-response-over-the-clinical-course-of-ms/?sc=rsin /articles/evolution-of-the-neuroinflammatory-response-over-the-clinical-course-of-ms/?sc=rsin Mon, 22 Feb 2021 13:05:42 EST Benjamin M. Segal, M.D., The Ohio State University, to present keynote address at ACTRIMS Forum 2021 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) The Spectrum of Multiple Sclerosis will be the focus at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum /articles/the-spectrum-of-multiple-sclerosis-will-be-the-focus-at-americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims-2021-forum/?sc=rsin /articles/the-spectrum-of-multiple-sclerosis-will-be-the-focus-at-americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims-2021-forum/?sc=rsin Tue, 19 Jan 2021 11:40:16 EST Forum Announcement Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Q&A with Leaders of MS Virtual 2020 Conference /articles/actrims-ms-virtual-2020-qa-with-association-leadership/?sc=rsin /articles/actrims-ms-virtual-2020-qa-with-association-leadership/?sc=rsin Sat, 26 Sep 2020 17:10:00 EST ACTRIMS MS Virtual 2020 Q&A with Association Leadership Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Evidence of an Increased Burden of Humoral Autoimmunity in the CSF and plasma of COVID-19 Patients with Comorbid Neurologic Dysfunction /articles/evidence-of-an-increased-burden-of-humoral-autoimmunity-in-the-csf-and-plasma-of-covid-19-patients-with-comorbid-neurologic-dysfunction/?sc=rsin /articles/evidence-of-an-increased-burden-of-humoral-autoimmunity-in-the-csf-and-plasma-of-covid-19-patients-with-comorbid-neurologic-dysfunction/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Coronavirus disease 19 (COVID-19) is the most globally impactful pandemic of the past century. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Neutrophil granulocyte markers in cerebrospinal fluid differentiate NMOSD and anti-MOG antibody associated disease from MS in acute disease phase /articles/neutrophil-granulocyte-markers-in-cerebrospinal-fluid-differentiate-nmosd-and-anti-mog-antibody-associated-disease-from-ms-in-acute-disease-phase/?sc=rsin /articles/neutrophil-granulocyte-markers-in-cerebrospinal-fluid-differentiate-nmosd-and-anti-mog-antibody-associated-disease-from-ms-in-acute-disease-phase/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 outcomes /articles/first-results-of-the-covid-19-in-ms-global-data-sharing-initiative-suggest-anti-cd20-dmts-are-associated-with-worse-covid-19-outcomes/?sc=rsin /articles/first-results-of-the-covid-19-in-ms-global-data-sharing-initiative-suggest-anti-cd20-dmts-are-associated-with-worse-covid-19-outcomes/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) COVID-19 in persons with multiple sclerosis treated with ocrelizumab: pharmacovigilance update /articles/covid-19-in-persons-with-multiple-sclerosis-treated-with-ocrelizumab-pharmacovigilance-update/?sc=rsin /articles/covid-19-in-persons-with-multiple-sclerosis-treated-with-ocrelizumab-pharmacovigilance-update/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis /articles/clinical-characteristics-and-outcomes-in-patients-with-coronavirus-disease-2019-and-multiple-sclerosis/?sc=rsin /articles/clinical-characteristics-and-outcomes-in-patients-with-coronavirus-disease-2019-and-multiple-sclerosis/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Comparison of COVID-19 outcomes between racial groups in the COViMS registry /articles/comparison-of-covid-19-outcomes-between-racial-groups-in-the-covims-registry/?sc=rsin /articles/comparison-of-covid-19-outcomes-between-racial-groups-in-the-covims-registry/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Interrupting disease modifying treatment for pregnancy in multiple sclerosis - effect on disease activity and serum neurofilament light chain /articles/interrupting-disease-modifying-treatment-for-pregnancy-in-multiple-sclerosis-effect-on-disease-activity-and-serum-neurofilament-light-chain/?sc=rsin /articles/interrupting-disease-modifying-treatment-for-pregnancy-in-multiple-sclerosis-effect-on-disease-activity-and-serum-neurofilament-light-chain/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Network analysis identifies gut bacteria associated with multiple sclerosis relapse among pediatric-onset patients /articles/network-analysis-identifies-gut-bacteria-associated-with-multiple-sclerosis-relapse-among-pediatric-onset-patients/?sc=rsin /articles/network-analysis-identifies-gut-bacteria-associated-with-multiple-sclerosis-relapse-among-pediatric-onset-patients/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Brain microstructural and metabolic alterations detected in vivo at the onset of the first demyelinating event /articles/brain-microstructural-and-metabolic-alterations-detected-in-vivo-at-the-onset-of-the-first-demyelinating-event/?sc=rsin /articles/brain-microstructural-and-metabolic-alterations-detected-in-vivo-at-the-onset-of-the-first-demyelinating-event/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis /articles/phase-2-clinical-trial-evidence-that-a-retinoid-x-receptor-agonist-promotes-remyelination-in-people-with-relapsing-remitting-multiple-sclerosis/?sc=rsin /articles/phase-2-clinical-trial-evidence-that-a-retinoid-x-receptor-agonist-promotes-remyelination-in-people-with-relapsing-remitting-multiple-sclerosis/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Primary astrocytopathy has a detrimental effect on remyelination efficacy of parenchymal oligodendrocyte precursor cells /articles/primary-astrocytopathy-has-a-detrimental-effect-on-remyelination-efficacy-of-parenchymal-oligodendrocyte-precursor-cells/?sc=rsin /articles/primary-astrocytopathy-has-a-detrimental-effect-on-remyelination-efficacy-of-parenchymal-oligodendrocyte-precursor-cells/?sc=rsin Fri, 25 Sep 2020 07:00:00 EST Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)